File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lamivudine in hepatitis B-associated membranous nephropathy

TitleLamivudine in hepatitis B-associated membranous nephropathy
Authors
KeywordsHepatitis B
Lamivudine
Membranous nephropathy
Proteinuria
Remission
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ki/index.html
Citation
Kidney International, 2005, v. 68 n. 4, p. 1750-1758 How to Cite?
AbstractBackground. Although lamivudine is effective for treatment of chronic hepatitis B (HBV) infection, its potential therapeutic impact on HBV-related membranous nephropathy (MN) in adults has not been characterized. Methods. We treated 10 HBsAg-positive patients with biopsy-proven MN, elevated serum alanine aminotransferase (ALT), and HBV-DNAemia (group 1), and compared their clinical course with 12 patients diagnosed to have HBV infection, elevated serum ALT, and MN in the pre-lamivudine era (group 2). Results. Baseline demographic and clinical parameters were not different between the 2 groups. In group 1, lamivudine treatment was associated with significant reduction in proteinuria, increase in serum albumin, normalization of ALT levels, and disappearance of circulating HBV-DNA during the first year. Four (40%) and 6 (60%) patients went into complete remission (proteinuria <0.3 g/d) at 6 and 12 months, respectively. In group 2, significant proteinuria persisted during the first year. One (8.3%) and 3 (25%) patients went into remission. Cumulative 3-year renal survival [using end-stage renal disease (ESRD) as primary end point] was 100% in group 1 and 58% in group 2 (P = 0.024, log rank test). Blood pressure control reached the target of below 130/85 mm Hg in both groups. Lamivudine was well tolerated and not associated with any adverse events. Hepatic decompensation or malignancy was not observed during follow-up in both groups. Conclusion. HBV-related MN leads to ESRD in a significant proportion of patients before the advent of antiviral therapy. Lamivudine treatment improves renal outcome in HBV carriers with MN and evidence of liver disease. © 2005 by the International Society of Nephrology.
Persistent Identifierhttp://hdl.handle.net/10722/77479
ISSN
2015 Impact Factor: 7.683
2015 SCImago Journal Rankings: 3.181
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, Sen_HK
dc.contributor.authorLai, FMMen_HK
dc.contributor.authorYun, HLen_HK
dc.contributor.authorTang, CSOen_HK
dc.contributor.authorKung, NNSen_HK
dc.contributor.authorYiu, WHen_HK
dc.contributor.authorKwok, WCen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorKar, NLen_HK
dc.date.accessioned2010-09-06T07:32:20Z-
dc.date.available2010-09-06T07:32:20Z-
dc.date.issued2005en_HK
dc.identifier.citationKidney International, 2005, v. 68 n. 4, p. 1750-1758en_HK
dc.identifier.issn0085-2538en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77479-
dc.description.abstractBackground. Although lamivudine is effective for treatment of chronic hepatitis B (HBV) infection, its potential therapeutic impact on HBV-related membranous nephropathy (MN) in adults has not been characterized. Methods. We treated 10 HBsAg-positive patients with biopsy-proven MN, elevated serum alanine aminotransferase (ALT), and HBV-DNAemia (group 1), and compared their clinical course with 12 patients diagnosed to have HBV infection, elevated serum ALT, and MN in the pre-lamivudine era (group 2). Results. Baseline demographic and clinical parameters were not different between the 2 groups. In group 1, lamivudine treatment was associated with significant reduction in proteinuria, increase in serum albumin, normalization of ALT levels, and disappearance of circulating HBV-DNA during the first year. Four (40%) and 6 (60%) patients went into complete remission (proteinuria <0.3 g/d) at 6 and 12 months, respectively. In group 2, significant proteinuria persisted during the first year. One (8.3%) and 3 (25%) patients went into remission. Cumulative 3-year renal survival [using end-stage renal disease (ESRD) as primary end point] was 100% in group 1 and 58% in group 2 (P = 0.024, log rank test). Blood pressure control reached the target of below 130/85 mm Hg in both groups. Lamivudine was well tolerated and not associated with any adverse events. Hepatic decompensation or malignancy was not observed during follow-up in both groups. Conclusion. HBV-related MN leads to ESRD in a significant proportion of patients before the advent of antiviral therapy. Lamivudine treatment improves renal outcome in HBV carriers with MN and evidence of liver disease. © 2005 by the International Society of Nephrology.en_HK
dc.languageengen_HK
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ki/index.htmlen_HK
dc.relation.ispartofKidney Internationalen_HK
dc.subjectHepatitis Ben_HK
dc.subjectLamivudineen_HK
dc.subjectMembranous nephropathyen_HK
dc.subjectProteinuriaen_HK
dc.subjectRemissionen_HK
dc.subject.meshAdulten_HK
dc.subject.meshBlood Pressureen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshGlomerulonephritis, Membranous - pathology - prevention & control - virologyen_HK
dc.subject.meshHepatitis B, Chronic - complications - drug therapy - pathologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKidney Failure, Chronic - pathology - prevention & control - virologyen_HK
dc.subject.meshLamivudine - administration & dosageen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshReverse Transcriptase Inhibitors - administration & dosageen_HK
dc.subject.meshSurvival Rateen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleLamivudine in hepatitis B-associated membranous nephropathyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0085-2538&volume=68&issue=4&spage=1750&epage=1758&date=2005&atitle=Lamivudine+in+hepatitis+B-associated+membranous+nephropathyen_HK
dc.identifier.emailTang, S: scwtang@hku.hken_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailKar, NL: knlai@hku.hken_HK
dc.identifier.authorityTang, S=rp00480en_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.identifier.authorityKar, NL=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1523-1755.2005.00591.xen_HK
dc.identifier.pmid16164651-
dc.identifier.scopuseid_2-s2.0-31644449225en_HK
dc.identifier.hkuros121461en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-31644449225&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume68en_HK
dc.identifier.issue4en_HK
dc.identifier.spage1750en_HK
dc.identifier.epage1758en_HK
dc.identifier.isiWOS:000231801300039-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTang, S=7403437082en_HK
dc.identifier.scopusauthoridLai, FMM=7202559720en_HK
dc.identifier.scopusauthoridYun, HL=36823696400en_HK
dc.identifier.scopusauthoridTang, CSO=8681865300en_HK
dc.identifier.scopusauthoridKung, NNS=36977766300en_HK
dc.identifier.scopusauthoridYiu, WH=23981838200en_HK
dc.identifier.scopusauthoridKwok, WC=36868807000en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridKar, NL=7402135706en_HK
dc.identifier.citeulike316939-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats